ASX Announcements

ASX Announcements

Due to legal restrictions, only residents of Australia and New Zealand may access ASX announcements that contain information or materials relating to any capital raising.

Date Title  
28 November 2023 CEO Presentation to 2023 Annual General Meeting
28 November 2023 Mesoblast Chairman Message to 2023 AGM
27 November 2023 MSB Files for FDA Designations in Congenital Heart Disease
22 November 2023 Mesoblast Partners with BMT CTN on Adult SR-aGVHD Trial
15 November 2023 Mesoblast Corporate Presentation
31 October 2023 Quarterly Activities/Appendix 4C Cash Flow Report
30 October 2023 Annual Report to Shareholders
30 October 2023 Notice of Annual General Meeting and Proxy Form
30 October 2023 Appendix 4G and Corporate Governance Statement
16 October 2023 Notification of cessation of securities - MSB
16 October 2023 Notification regarding unquoted securities - MSB
29 September 2023 Final Director's Interest Notice
26 September 2023 Jane Bell Appointed Chair of Audit and Risk Committee
21 September 2023 Mesoblast Type A Meeting with FDA
31 August 2023 MSB Annual Financial Results and Operational Update
31 August 2023 Annual Financial Results Presentation
31 August 2023 Preliminary Final Report including Appendix 4E
29 August 2023 Mesoblast 2023 Full Year Financial Results Webcast
29 August 2023 Change in substantial holding
11 August 2023 Ceasing to be a substantial holder
10 August 2023 Ceasing to be a substantial holder
10 August 2023 Change in substantial holding
09 August 2023 Change in substantial holding
09 August 2023 Change in substantial holding
04 August 2023 Update on BLA for Graft Versus Host Disease
03 August 2023 Change in substantial holding
02 August 2023 Trading Halt
01 August 2023 Change in substantial holding
31 July 2023 Quarterly Activities/Appendix 4C Cash Flow Report
07 July 2023 Appendix 3G, Appendix 3H and Appendix 3Ys
13 June 2023 Change of Director's Interest Notice
05 June 2023 Mesoblast Director Appointed to Strategic Advisory Role
26 May 2023 MSB Reports Q3 Financial Results and Operational Highlights
26 May 2023 Third Quarter Results Presentation
26 May 2023 Third Quarter Financial Results on Form 6-K
24 May 2023 Mesoblast Third Quarter Financial Results Webcast
03 May 2023 Becoming a substantial holder
03 May 2023 Change in substantial holding
01 May 2023 Cleansing Notice
28 April 2023 Application for quotation of securities - MSB
28 April 2023 Quarterly Activities/Appendix 4C Cash Flow Report
26 April 2023 Reinstatement to Official Quotation
26 April 2023 Proposed issue of securities - MSB
26 April 2023 Mesoblast Completes Private Placement
24 April 2023 Voluntary Suspension
20 April 2023 Trading Halt
20 April 2023 Pause in Trading
22 March 2023 FDA Schedules GvHD Pre-License Manufacturing Inspection
15 March 2023 Appendix 3G and Appendix 3H
08 March 2023 FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L
08 March 2023 Pause in Trading
03 March 2023 Prospectus for Warrants Related to Oaktree Facility
28 February 2023 DREAM HF Trial Published in JACC
28 February 2023 MSB Q2 Financial Results and Operational Highlights
28 February 2023 Second Quarter Results Presentation
28 February 2023 Half Yearly Report and Accounts
27 February 2023 Mesoblast Second Quarter Financial Results Webcast
17 February 2023 Remestemcel Clinical and Potency Studies Presented at Tandem
09 February 2023 FDA Grants RMAT Designation for Rexlemestrocel-L in CLBP
01 February 2023 Mesoblast Completes Resubmission of BLA to FDA for SR-aGVHD
31 January 2023 Quarterly Activities/Appendix 4C Cash Flow Report
16 January 2023 Appendix 3G, Appendix 3H and Appendix 3Ys
10 January 2023 Biotech Showcase 2023 Presentation in San Francisco

Share Price :    as of Oct 06, 2023